Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 10, 2005, Pages 1161-1167

  Hillemann, Doris ^a   Kubica, T ^a   Agzamova, R ^b   Venera, B ^b   Rusch Gerdes S ^a   Niemann, S ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b National Center for Tuberculosis Problems   (Kazakhstan)

Author keywords

Kazakhstan; MDR TB; Mutations; Resistance

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; GENOTYPE; KAZAKHSTAN; MULTIDRUG RESISTANCE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CODON; GENOTYPE; HUMANS; ISONIAZID; KAZAKHSTAN; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 26444571695     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
2. EUROTB 2003: Surveillance of tuberculosis in Europe. WHO Collaborating Centre. Saint Maurice, France: Institut de Veille Sanitaire, 2003. www.eurotb.org/eurotb.htm Accessed October 2004.
3. United States Agency for International Development. CAR-Central Asia Infectious Diseases Network. USAID program for Control and Prevention of Infectious Diseases in Central Asia. Washington, DC: USAID, 2004. www.usaid.gov/regions/europe_ eurasia/car/hiv_aids/hope.htm Accessed November 2004.
4. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Third Global Report. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, 1999-2002. WHO/HTM/TB/2004.343. Geneva, Switzerland: WHO, 2004.
5. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202.
6. Drobniewski F A, Balabanova Y M. The diagnosis and management of multiple-drug-resistant-tuberculosis at the beginning of the new millenium. Int J Infect Dis 2002; 6 (Suppl 1): 21-31.
7. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculous. In: Harfull G F, Jacobs W R, Jr eds. Molecular genetics of mycobacteria. Washington, DC: ASM Press, 2000: pp 235-251.
8. Mdluli, K, Sherman D R, Hickey M J, et al. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1085-1090.
9. Mdluli K, Slayden R A, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-1610.
10. Musser J M, Kapur V, Williams D L, Kreiswirth B N, van Soolingen D, van Embden J D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996; 173: 196-202.
11. Ramaswamy, S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis 1998; 79: 23-29.
12. Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser J M. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41: 600-606.
13. Telenti, A, Honoré N, Bernasconi C, et al. Genotyping assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 713-719.
14. Heep M, Brandtstätter B, Rieger U, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39: 107-110.
15. Munsiff S S, Bassoff T, Nivin B, et al. Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. Emerg Infect Dis 2002; 8: 1230-1238.
16. Niemann S, Rüsch-Gerdes S, Richter E. IS6110 fingerprinting of drug-resistant Mycobacterium tuberculosis strains isolated in Germany during 1995. J Clin Microbiol 1997; 35: 3015-3020.
17. Bifani P J, Mathema B, Kurepina N E, Kreiswirth B N. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002; 10: 45-52.
18. Glynn J R, Whiteley J, Bifani P J, Kremer K, Van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 843-849.
19. Kruuner A, Hoffner S E, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39: 3339-3345.
20. Kubica T, Agzamova R, Wright A, et al. The Beijing genotype is a major cause of drug resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2005; 9: 646-653.
21. Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears. Antimicrob Agents Chemother 2003; 47: 2231-2235.
22. Qian, L, Abe C, Lin T-P, et al. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol 2002; 40: 1091-1094.
23. World Health Organization. WHO Laboratory Services in tuberculosis control. Part III: culture. WHO/TB/98.258. Geneva, Switzerland: WHO, 1998.
24. Deutsches Institut für Normung eV (DIN). Medizinische Mikrobiologie, Tuberkulosediagnostik. Berlin, Germany: Beuth Verlag, Norm 58943-8, 1996 and 58943-9, 1993.
25. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneus detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
26. van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001; 249: 1-26.
27. Sajduda A, Brzostek A, Poplawska M, et al. Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J Clin Microbiol 2004; 42: 2425-2431.
28. Bártfai, Z, Somoskövi A, Ködmön C, et al. Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol 2001; 39: 3736-3739.
29. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevkiy B. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from Northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417-1424.
30. Tracevska, T, Jansone I, Broka L, Marga O, Baumanis V. Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol 2002; 40: 3789-3792.
31. Bakonyte D, Baranauskaite A, Cicenaite J, Sosnovskaja A, Stakenas P. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob Agents Chemother 2003; 47: 2009-2011.
32. Pym A S, Saint-Joanis B, Cole S T. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-4960.
33. van Soolingen D, de Haas P E, van Doom H R, Kuijper E, Rinder H, Borgdorff M W. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788-1790.
34. Drobniewski F, Balabanova Y, Ruddy M, et al. Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the Beijing strain family. Emerg Infect Dis 2002; 8: 1320-1326.
35. Mokrousov I, Otten T, Vyazovaya A, et al. PCR-based methodology for detecting multidrug-resistant strains of Mycobacterium tuberculosis Beijing family circulating in Russia. Eur J Clin Microbiol Infect Dis 2003; 22: 342-348.